## Edgar Filing: MYLAN INC. - Form 4

MAXE AND INCO

Form 4										
February 27,									PPROVAL	
FORM	4 UNITED S	TATES SECUI Wa				IGE (	COMMISSION	-	3235-0287	
Check this if no long subject to Section 16 Form 4 or Form 5 obligation may conti <i>See</i> Instru- 1(b).	Filed purs Section 17(a	<b>STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b> Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section						burden hou response	Estimated average burden hours per response 0.5	
(Print or Type R	esponses)									
PARRISH MARK W Symbol			r Name <b>and</b> Ticker or Trading N INC. [MYL]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Month/Da           1000 MYLAN BLVD         02/27/20           (Street)         4. If Amen			Pate of Earliest Transaction onth/Day/Year) 27/2015 <sup>7</sup> Amendment, Date Original d(Month/Day/Year)				X Director 10% Owner Officer (give title Other (specify below) 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
(City)	(State) (2	Zip) Tab	le I - Non-De	erivative S	ecurit	ies Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	4. Securit on(A) or Dis (D) (Instr. 3, 4)	sposed	of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
$\frac{\text{Common}}{\text{Stock } (1) (2)}$	02/27/2015		D	29,660	D	<u>(3)</u>	0	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: MYLAN INC. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number prof Derivativ Securities Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securiti (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisat	Expiration le Date	Title	Amou or Numb of Share
Non-Employee Director Stock Option - Right to Buy <sup>(4)</sup>	\$ 45.72	02/27/2015		D	2,97	4 <u>(5)</u>	04/11/2024	Common Stock	2,97

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
PARRISH MARK W							
1000 MYLAN BLVD	Х						
CANONSBURG, PA 15317							
Signatures							
/s/ Bradley L. Wideman, by power of attorney		02/27/2015					
**Signature of Reporting Person	n	Date					

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On February 27, 2015 (the "Closing Date"), Mylan N.V. completed the transaction (the "Transaction") by which it acquired Mylan Inc. and Abbott Laboratories' ("Abbott") non-U.S. developed markets specialty and branded generics business (the "Business"). Pursuant to the terms of the Amended and Restated Business Transfer Agreement and Plan of Merger, dated as of November 4, 2014, by and among Mylan Inc., New Moon B.V. (which has been renamed Mylan N.V. and is referred to herein as "Mylan"), Moon of PA Inc. ("Merger

Mylan Inc., New Moon B.Y. (which has been renanced Mylan N.Y. and is referred to herein as "Mylan"), Moon of FA inc. ("Merger")
 Sub"), and Abbott, on the Closing Date, Mylan acquired the Business and Merger Sub merged with and into Mylan Inc., with Mylan Inc. surviving as a wholly owned indirect subsidiary of Mylan and each share of Mylan Inc. common stock issued and outstanding was cancelled and automatically converted into and became the right to receive one Mylan ordinary share (the "Merger"). (Continued in footnote 2)

In connection with the Transaction, Mylan Inc. and the Business have been reorganized under Mylan, a new public company organized in the Netherlands. This report is being filed by the reporting person solely to report the disposition of shares of Mylan Inc. common stock in

- (2) the reculting the report is being filed by the reporting person solery to report the disposition of shares of Mylan inc. common stock in Mylan in connection with the Transaction.
- (3) Represents shares of Mylan Inc. common stock that were exchanged on a one-for-one basis for Mylan ordinary shares in connection with the Transaction. On the effective date of the Merger, the closing price of MYL was \$57.33 per share.
- (4) Represents stock options of Mylan Inc. common stock that were exchanged for stock options of Mylan ordinary shares having substantially the same terms in connection with the Transaction.

## Edgar Filing: MYLAN INC. - Form 4

(5) These options will vest in full on April 11, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.